A POWERFUL RESEARCH AND
DEVELOPMENT ENGINE

Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

Interact with the Regeneron Pipeline

Pipeline last updated:
Select Therapeutic Area(s):
Select Phase(s):
Select Collaborator(s):

Displaying item(s)

Clear Filters

Regeneron Pipeline: Phase 1 Medicines Regeneron Pipeline: Phase 1 Medicines
  • CEMIPLIMAB*
    PD-1 Antibody Cancer
  • REGN3767
    LAG-3 Antibody Solid tumors, advanced hematologic malignancies
  • REGN6569
    GITR Antibody Solid tumors
  • ODRONEXTAMAB
    CD20 X CD3 Antibody B-cell malignancies
  • REGN4018*
    MUC16 X CD3 Antibody Platinum-resistant ovarian cancer
  • REGN5459*
    BCMA X CD3 Antibody Multiple myeloma
  • REGN5678
    PSMA X CD28 Antibody Prostate cancer
  • REGN5093
    MET X MET Antibody MET-altered advanced non-small cell lung cancer (NSCLC)
  • REGN5713-5714-5715
    Bet v 1 Antibodies Birch Allergy
  • REGN7257
    IL2Rg Antibody Aplastic anemia
  • Casirivimab and imdevimab
    SARS-CoV-2 Virus Multi-Antibody Therapy Multi-dose safety study in healthy volunteers
  • REGN5381
    NPR1 Agonist Antibody Heart failure
Regeneron Pipeline: Phase 2 Medicines Regeneron Pipeline: Phase 2 Medicines
  • AFLIBERCEPT
    VEGF-Trap High-dose (8mg) for wet age-related macular degeneration (AMD)
  • CEMIPLIMAB*
    PD-1 Antibody Basal cell carcinoma (BCC), metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC
  • ODRONEXTAMAB
    CD20 X CD3 Antibody B-cell non-Hodgkin lymphoma
  • REGN5458*
    BCMA X CD3 Antibody Multiple myeloma
  • SARILUMAB*
    IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis
  • DUPILUMAB*
    IL-4R Antibody Peanut allergy, grass allergy
  • REGN1908-1909
    Fel d 1 Multi-Antibody Therapy Cat allergy
  • ITEPEKIMAB*
    IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD)
  • EVINACUMAB
    ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia
  • POZELIMAB
    C5 Antibody Paroxysmal nocturnal hemoglobinuria, CD-55 deficient protein-losing enteropathy
  • REGN4461
    LEPR Agonist Antibody Generalized lipodystrophy
  • GARETOSMAB
    Activin-A Antibody Fibrodysplasia Ossificans Progressiva (FOP)
Regeneron Pipeline: Phase 3 Medicines Regeneron Pipeline: Phase 3 Medicines
  • AFLIBERCEPT
    VEGF-Trap Retinopathy of prematurity (ROP), high-dose formulation (8mg) for wet age-related macular degeneration (AMD) and diabetic macular edema (DME)
  • CEMIPLIMAB*
    PD-1 Antibody non-small cell lung cancer (NSCLC), cervical cancer, adjuvant cutaneous squamous cell carcinoma (CSCC)
  • DUPILUMAB*
    IL-4R Antibody Atopic dermatitis in pediatric patients 6 mo.–11 y.o., asthma in pediatric patients 6-11 y.o., eosinophilic esophagitis in patients 6 and older, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria, allergic bronchopulmonary aspergillosis
  • Casirivimab and imdevimab
    SARS-CoV-2 Virus Multi-Antibody Therapy Treatment for certain hospitalized and non-hospitalized patients with COVID-19; prevention of COVID-19 in household contacts of diagnosed patients
  • ALIROCUMAB*
    PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatric patients, heterozygous familial hypercholesterolemia (HeFH) in pediatric patients
  • EVINACUMAB
    ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)
  • FASINUMAB†
    NGF Antibody Osteoarthritis pain of the knee or hip

No results found, please adjust your filter selection and try again.

* In collaboration with Sanofi

† In collaboration with Teva and Mitsubishi Tanabe

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.